Chapter-4.

DEMYELINATING DISORDERS AND VISUAL DYSFUNCTION

Dr Partha Chowdhury, Dr Brinda Shah

ABSTRACT

Demyelinating disorders, including Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD), and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD), are among the leading causes of acquired visual impairment in young and middle-aged adults. These immune-mediated disorders primarily affect the myelin sheath of the central nervous system, resulting in disrupted neural conduction, axonal injury, and progressive visual dysfunction. The visual pathways, particularly the optic nerves, are highly susceptible to demyelinating damage, making optic neuritis the most common ophthalmic manifestation. In addition to reduced visual acuity, patients frequently experience impaired colour vision, decreased contrast sensitivity, visual field defects, ocular motor abnormalities, and higher-order visual processing deficits. Recent advances in optical coherence tomography (OCT), magnetic resonance imaging (MRI), visual evoked potentials (VEPs), and retinal biomarkers have significantly improved the early diagnosis, disease monitoring, and prognostic assessment of these conditions. Furthermore, treatment strategies have evolved beyond conventional immunosuppressive therapy to include targeted immunomodulation, remyelination therapies, neuroprotective interventions, and comprehensive visual rehabilitation.

Keywords: Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease, Optic Neuritis, Visual Dysfunction.

4.1 INTRODUCTION

Demyelinating disorders are a group of immune-mediated diseases of the central nervous system (CNS) characterized by the destruction of the myelin sheath and subsequent axonal injury, leading to impaired neural conduction and progressive neurological dysfunction (Costello, 2013; Levin & Bennett, 2017). Among these conditions, Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD), and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) are the leading causes of acquired visual impairment in young and middle-aged adults (Jarius et al., 2020; Toosy et al., 2014). The visual pathways are particularly vulnerable because the optic nerves, optic chiasm, optic tracts, and optic radiations contain densely myelinated axons that are highly susceptible to immune-mediated demyelination. Damage to these structures disrupts the transmission of visual information, resulting in a wide range of visual deficits, with optic neuritis being the most common and often the earliest clinical manifestation (Galetta et al., 2015; Hickman et al., 2018). Visual dysfunction in demyelinating disorders extends beyond the afferent visual pathway. Demyelinating lesions involving the brainstem and cerebellum frequently affect ocular motor pathways, leading to abnormalities such as internuclear ophthalmoplegia, nystagmus, impaired smooth pursuit, and binocular vision disorders that significantly compromise visual stability and coordination (Frohman et al., 2008; Levin & Bennett, 2017). These visual disturbances can substantially reduce reading ability, mobility, occupational performance, and overall quality of life (Balk et al., 2018). Importantly, the visual system provides a unique and accessible model for studying central nervous system pathology, as structural and

functional changes can be directly assessed using modern diagnostic techniques such as Optical Coherence Tomography (OCT), Visual Evoked Potentials (VEPs), and Magnetic Resonance Imaging (MRI) (Balcer et al., 2017; Frohman et al., 2008). Consequently, evaluation of visual function has become an essential component in the diagnosis, monitoring, and therapeutic assessment of demyelinating diseases, while advances in neuroimaging, immunotherapy, and neuroprotective strategies continue to improve clinical outcomes and patient care.

4.2 PATHOPHYSIOLOGY OF VISUAL DYSFUNCTION

Visual dysfunction in demyelinating disorders arises from three interrelated mechanisms: demyelination, axonal injury, and impaired remyelination (Costello, 2013; Levin & Bennett, 2017). Demyelination disrupts saltatory conduction, resulting in conduction slowing or block, which clinically manifests as visual blurring, reduced contrast sensitivity, and Uhthoff's phenomenon (Toosy et al., 2014). Redistribution of sodium channels along the axolemma may partially restore conduction but increases metabolic demand, rendering axons vulnerable to degeneration (Levin & Bennett, 2017). Axonal degeneration is a major determinant of irreversible disability. Acute inflammatory attacks can cause axonal transection, while chronic demyelination accelerates progressive axonal loss (Saidha et al., 2015). This structural damage correlates strongly with retinal nerve fibre layer (RNFL) thinning observed on optical coherence tomography (OCT) (Petzold et al., 2017; Saidha et al., 2015). Failure of remyelination further contributes to cumulative neurological injury. Although oligodendrocyte precursor cells attempt repair, chronic inflammation and gliosis frequently impair effective remyelination (Costello, 2013). In NMOSD, astrocytic injury mediated by aquaporin-4 antibodies adds an additional layer of irreversible damage, accounting for poorer visual recovery compared with MS (Jarius et al., 2020; Wingerchuk et al., 2015).

4.3 CLINICAL MANIFESTATIONS

Optic Neuritis: Optic neuritis is the most common ophthalmic manifestation of demyelinating disorders and often represents the initial presentation of Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD), or Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD). It typically presents with acute or subacute unilateral visual loss accompanied by pain during eye movement. Patients commonly experience blurred vision, central visual field defects, impaired colour vision particularly red desaturation and reduced contrast sensitivity, often disproportionate to the degree of visual acuity loss (Hickman et al., 2018; Toosy et al., 2014). Visual recovery in MS is generally favourable, although subtle deficits in contrast sensitivity and colour discrimination may persist. In contrast, optic neuritis associated with NMOSD is usually more severe, frequently bilateral, and carries a higher risk of permanent visual impairment despite treatment (Balcer et al., 2017; Bennett et al., 2015; Jarius et al., 2020).

Uhthoff's Phenomenon: Uhthoff's phenomenon is a characteristic feature of demyelinating disease, characterized by a temporary worsening of visual function following increased body temperature caused by exercise, fever, or exposure to heat. This reversible deterioration results from impaired impulse conduction in demyelinated optic nerve fibres and typically resolves once body temperature returns to normal (Toosy et al., 2014).

Visual Fatigue and Oscillopsia: Many patients experience visual fatigue, characterized by progressive blurring and reduced visual performance during prolonged visual activities such as reading or computer use. This is thought to result from impaired conduction and metabolic stress within demyelinated nerve fibres. Oscillopsia, the illusion that stationary objects are moving, occurs when demyelination affects brainstem or cerebellar pathways controlling eye movements, leading to nystagmus and impaired gaze stabilization (Frohman et al., 2008; Levin & Bennett, 2017).

Ocular Motor Disorders: Demyelinating lesions frequently involve the brainstem ocular motor pathways, producing characteristic eye movement abnormalities. Internuclear ophthalmoplegia (INO), caused by demyelination of the medial longitudinal fasciculus (MLF), is considered one of the most specific ocular motor signs of MS. It presents with impaired adduction of the affected eye, abducting nystagmus of the opposite eye, and binocular diplopia. Additional ocular motor abnormalities, including gaze-evoked nystagmus, skew deviation, saccadic dysmetria, and impaired smooth pursuit, may occur due to involvement of the brainstem and cerebellum, resulting in impaired binocular vision, visual instability, and reduced visual comfort (Frohman et al., 2008; Levin & Bennett, 2017).

4.4 DIAGNOSTIC APPROACHES

Accurate diagnosis of visual dysfunction in demyelinating disorders requires a combination of structural imaging, functional assessment,

electrophysiological testing, and serological evaluation. Optical Coherence Tomography (OCT) is a valuable, non-invasive technique that measures the thickness of the retinal nerve fibre layer (RNFL) and ganglion cell layer, providing objective evidence of axonal loss and retinal neurodegeneration in Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD), and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) (Balk et al., 2018; Petzold et al., 2017; Zimmermann et al., 2018). Visual Evoked Potentials (VEPs) evaluate the functional integrity of the optic pathway by measuring the latency of the P100 waveform. Prolonged P100 latency is a characteristic finding of optic nerve demyelination and is particularly useful for detecting subclinical optic neuritis (Toosy et al., 2014). Magnetic Resonance Imaging (MRI) remains the gold standard for identifying inflammatory demyelinating lesions within the optic nerves, optic radiations, and brain. Acute optic neuritis is characterized by optic nerve enhancement on T1-weighted post-contrast images, while T2-weighted hyperintensities indicate chronic demyelinating lesions. Advanced MRI techniques, including diffusion tensor imaging (DTI) and magnetization transfer imaging (MTI), provide additional information regarding axonal integrity and myelin damage (Costello, 2013). Comprehensive functional assessment includes high- and low-contrast visual acuity testing, automated visual field analysis, colour vision assessment, and contrast sensitivity evaluation, with low-contrast letter acuity serving as a sensitive marker of early visual dysfunction (Balcer et al., 2017). In suspected NMOSD and MOGAD, serological testing for aquaporin-4 (AQP4-IgG) and myelin oligodendrocyte glycoprotein (MOG-IgG) antibodies is essential for differentiating these disorders from MS and guiding appropriate immunotherapy (Jarius et al., 2020; Wingerchuk et al., 2015).

4.5 MANAGEMENT STRATEGIES

Management of visual dysfunction in demyelinating disorders focuses on treating acute inflammatory episodes, preventing disease progression, and maximizing visual function through rehabilitation. High-dose intravenous corticosteroids are the first-line treatment for acute optic neuritis, accelerating visual recovery, although they have limited impact on long-term visual outcomes (Galetta et al., 2015). In patients with severe or steroid-resistant optic neuritis, particularly those with Neuromyelitis Optica Spectrum Disorder (NMOSD), plasma exchange (PLEX) or intravenous immunoglobulin (IVIG) may be used to reduce immune-mediated damage and improve visual recovery (Jarius et al., 2020). Long-term management includes disease-modifying therapies (DMTs) to reduce relapse frequency and slow disease progression. In Multiple Sclerosis (MS), medications such as interferons, fingolimod, natalizumab, and newer immunomodulatory agents decrease the risk of recurrent optic neuritis and neurological disability (Levin & Bennett, 2017). For NMOSD, targeted biological therapies including eculizumab, inebilizumab, and satralizumab have significantly reduced relapse rates and improved visual outcomes by suppressing antibody-mediated inflammation (Pittock et al., 2019). Visual rehabilitation plays an equally important role and includes low-vision aids, contrast-enhancing devices, prism correction, ocular motor exercises, and assistive technologies to improve daily functioning and quality of life. Emerging therapeutic approaches, including remyelination therapies, stem cell-based treatments, and neuroprotective interventions, offer promising opportunities to restore neural function and preserve vision (Levin & Bennett, 2017).

4.6 FUTURE PERSPECTIVES

Rapid advances in immunotherapy, neuroimaging, regenerative medicine, and digital rehabilitation are transforming the management of demyelinating visual disorders. Optical Coherence Tomography (OCT)-derived retinal biomarkers are increasingly used to monitor neuroaxonal damage and evaluate treatment response in clinical practice and research (Petzold et al., 2017; Zimmermann et al., 2018). Novel therapies aimed at promoting remyelination, neuroprotection, gene therapy, and targeted biologics have the potential to improve long-term visual outcomes. In addition, virtual reality-based visual rehabilitation, artificial intelligence-assisted monitoring, and tele-neuro-ophthalmology are expected to enhance personalized patient care. As the visual pathway provides a sensitive and accessible model of central nervous system demyelination, continued research is likely to advance both the understanding and treatment of these disorders, ultimately improving visual function and quality of life for affected patients (Frohman et al., 2008; Levin & Bennett, 2017).

4.7 CONCLUSION

Visual dysfunction is a major cause of disability in demyelinating disorders such as Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD), and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD). Immune-mediated damage to the optic

pathways results in optic neuritis, ocular motor abnormalities, and persistent deficits in visual function that can significantly affect quality of life. Advances in diagnostic modalities, including Optical Coherence Tomography (OCT), Magnetic Resonance Imaging (MRI), Visual Evoked Potentials (VEPs), and disease-specific antibody testing, have greatly improved early diagnosis and disease monitoring. Current management combines acute immunotherapy, disease-modifying treatments, and comprehensive visual rehabilitation to preserve vision and reduce long-term disability. Emerging therapies targeting remyelination, neuroprotection, regenerative medicine, and personalized rehabilitation offer promising opportunities for restoring visual function. Continued research into the mechanisms of demyelination and innovative therapeutic strategies will further enhance patient outcomes and improve the long-term management of visual disorders associated with demyelinating diseases.

4.8 BIBLIOGRAPHY

1. Balk LJ, Coric D, Knier B, Zimmermann HG, Behbehani R, Alroughani R, et al. Retinal atrophy in relation to visual functioning and vision-related quality of life in multiple sclerosis. Mult Scler J. 2018;24(6):767-76. doi:10.1177/1352458517708463.
2. Bennett JL, de Seze J, Lana-Peixoto M, Palace J, Waldman A, Schippling S, et al. Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography. Mult Scler J. 2015;21(6):678-88. doi:10.1177/1352458514567216.
3. Costello F. The afferent visual pathway: Designing a structural-functional paradigm of multiple sclerosis. ISRN Neurol. 2013;2013:134858. doi:10.1155/2013/134858.
4. Frohman EM, Fujimoto JG, Frohman TC, Calabresi PA, Cutter G, Balcer LJ. Optical coherence tomography: A window into the mechanisms of multiple sclerosis. Nat Rev Neurol. 2008;4(12):664-75. doi:10.1038/ncpneuro0950.
5. Galetta SL, Villoslada P, Levin N, Shindler K, Ishikawa H, Parr E, et al. Acute optic neuritis: Unmet clinical needs and model for new therapies. Neurol Neuroimmunol Neuroinflamm. 2015;2(4):e135. doi:10.1212/NXI.0000000000000135.
6. Hickman SJ, Ko M, Chaudhry F, Jayaram H, Plant GT. Optic neuritis: An update on typical and atypical optic neuritis. Neuroophthalmology. 2018;42(2):76-86. doi:10.1080/01658107.2017.1327614.
7. Jarius S, Paul F, Weinshenker BG, Levy M, Kim HJ, Wildemann B. Neuromyelitis optica spectrum disorders. Nat Rev Dis Primers. 2020;6(1):85. doi:10.1038/s41572-020-0214-9.
8. Levin MH, Bennett JL. Vision in multiple sclerosis: The story, structure-function correlations, and models for neuroprotection. J Neuroophthalmol. 2017;37(3):222-33. doi:10.1097/WNO.0000000000000507.
9. Petzold A, Balcer LJ, Calabresi PA, Costello F, Frohman TC, Frohman EM, et al. Retinal layer segmentation in multiple sclerosis: A systematic review and meta-analysis. Lancet Neurol. 2017;16(10):797-812. doi:10.1016/S1474-4422(17)30278-8.
10. Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(7):614-25. doi:10.1056/NEJMoa1900866.
11. Saidha S, Al-Louzi O, Ratchford JN, Bhargava P, Oh J, Newsome SD, et al. Optical coherence tomography reflects brain atrophy in multiple sclerosis: A four-year study. Ann Neurol. 2015;78(5):801-13. doi:10.1002/ana.24487.
12. Toosy AT, Mason DF, Miller DH. Optic neuritis. Lancet Neurol. 2014;13(1):83-99. doi:10.1016/S1474-4422(13)70259-X.
13. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-89. doi:10.1212/WNL.0000000000001729.
14. Zimmermann HG, Knier B, Oberwahrenbrock T, Behrens J, Pfuhl C, Aly L, et al. Association of retinal ganglion cell layer thickness with future disease activity in patients with clinically isolated syndrome. JAMA Neurol. 2018;75(9):1071-79. doi:10.1001/jamaneurol.2018.1011.
15. Balcer LJ, Raynowska J, Nolan R, Galetta SL, Kapoor R, Benedict R, et al. Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis. Mult Scler J. 2017;23(5):734-47. doi:10.1177/1352458517690822.